Disease Associated Microglia is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Disease-associated microglia (DAM) are a specialized subset of microglia that adopt a distinct transcriptional and functional profile in response to neurodegenerative disease processes. These cells represent a continuum of activation states, progressing from a homeostatic surveillance state to a disease-associated phenotype characterized by upregulated genes involved in phagocytosis, lysosomal function, and neuroinflammation.
The DAM phenotype was first characterized in mouse models of Alzheimer's disease and has since been identified in human neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis. These cells play complex roles in neurodegeneration, functioning both as defenders that clear toxic protein aggregates and as contributors to chronic neuroinflammation that drives disease progression.
Key markers of DAM include genes such as TREM2, APOE, CD74, and CST3, which are involved in lipid metabolism, immune response, and protein clearance. The activation of microglia to a DAM state is thought to be triggered by recognition of pathological hallmarks such as amyloid plaques, neurofibrillary tangles, or α-synuclein aggregates.
Disease-associated microglia (DAM) are a specialized microglial phenotype that emerges in neurodegenerative conditions. They are characterized by distinct transcriptional signatures and functional changes.
The study of Disease Associated Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.